Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03937154 · ClinicalTrials.gov registry record · Phase 3
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer
A Phase 3 study of Chemotherapy Induced Thrombocytopenia, sponsored by Amgen.
- Active
- Registry status
- Phase 3
- Development phase
- 145
- Enrollment target
- 20
- Study locations
NCT03937154: Active Phase 3 study of Chemotherapy Induced Thrombocytopenia, sponsored by Amgen.
NCT03937154 is a Phase 3 study of Chemotherapy Induced Thrombocytopenia that is active but no longer recruiting, run by Amgen. The registered enrollment target is 145 participants, above the 79-participant average among 4 other Chemotherapy Induced Thrombocytopenia trials with a reported enrollment target (84% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03937154, a Phase 3 study of Chemotherapy Induced Thrombocytopenia, is active but no longer recruiting, sponsored by Amgen.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 145 participants
- Enrollment target
- 20
- Study locations
Study Summary
To evaluate the efficacy of romiplostim for the treatment of CIT in patients receiving chemotherapy for the treatment of NSCLC, ovarian cancer, or breast cancer measured by the ability to administer on-time, full-dose chemotherapy
Primary Outcome
No thrombocytopenia-induced modification of any myelosuppressive agent in the second and third cycles of the planned on-study chemotherapy regimen. Thrombocytopenia-induced modifications include chemotherapy dose reduction, delay, omission, or chemotherapy treatment discontinuation due to platelet counts below 100 x 109/L
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Romiplostim
Study Locations (20)
Florida
- University of Miami School of Medicine - Miami
- Ocala Oncology Center - Ocala
- Mid Florida Hematology and Oncology Centers PA - Orange City
Louisiana
- Christus Saint Frances Cabrini Hospital - Alexandria
- University Medical Center New Orleans - New Orleans
- Christus Highland Cancer Treatment Center - Shreveport
California
- Los Angeles Cancer Network - Anaheim
- University of California Irvine - Orange
Illinois
- University of Chicago - Chicago
- Orchard Healthcare Research Inc - Skokie
Maryland
- Mercy Medical Center - Baltimore
- American Oncology Partners, PA - Bethesda
Arkansas
- Saint Bernards Medical Center - Jonesboro
Colorado
- Colorado West Healthcare System dba Grand Valley Oncology - Grand Junction
Idaho
- Saint Alphonsus Regional Medical Center - Boise
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 145 participants |
| Start Date | 2020-02-26 |
| Est. Completion | 2027-05-20 |
| Phase | Phase 3 |
What the registry record for NCT03937154 still lists
NCT03937154 is an interventional study that assigns participants to a tested intervention. The registered 145 participants enrollment target is mid-sized for trials with a published cap, above the 79-participant average among 4 other Chemotherapy Induced Thrombocytopenia trials with a reported enrollment target (84% higher).
The record links to 1 condition, with Chemotherapy Induced Thrombocytopenia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03937154 names 20 study sites across 13 states, led by Florida, Louisiana, California.
Frequently Asked Questions
What is clinical trial NCT03937154 about?
NCT03937154 is a clinical study titled "Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer". To evaluate the efficacy of romiplostim for the treatment of CIT in patients receiving chemotherapy for the treatment of NSCLC, ovarian cancer, or breast cancer measured by the ability to administer on-time, full-dose chemotherapy
What is the current status of trial NCT03937154?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 145 participants. The study started on 2020-02-26. Estimated completion is 2027-05-20.
What conditions does trial NCT03937154 study?
This clinical trial studies the following conditions: Chemotherapy Induced Thrombocytopenia.
What interventions are being tested in trial NCT03937154?
The interventions under investigation include: Placebo (DRUG), Romiplostim (DRUG).
Who is sponsoring clinical trial NCT03937154?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03937154 being conducted?
This trial has 20 study locations across Arkansas, California, Colorado, Florida, Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chemotherapy Induced Thrombocytopenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
COMPLETED · Phase 3
-
Single Arm Romiplostim to Prevent CIT
RECRUITING · Early Phase 1
-
Avatrombopag vs. Placebo for CIT in GI Malignancies
ACTIVE NOT RECRUITING · Phase 2
-
Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC)
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02688959 · 145 participants · NA
Motor Attention Training for Attention Deficit Hyperactivity Disorder (ADHD)
- NCT03586609 · 145 participants · Phase 2
Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia
- NCT03767595 · 145 participants · NA
ProACT Post-Approval Study
- NCT03808337 · 145 participants · Phase 2
Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI